Ion transport through a porphyrin-terminated hybrid bilayer membrane

College of Chemistry and Materials Science, Anhui Normal University, 1# Beijing East Rd, Wuhu 241000, Anhui, China; Institute of Biomaterial, College of Science, South China Agricultural University, Guangzhou 510642, China
Electrochimica Acta 01/2011; DOI: 10.1016/j.electacta.2010.10.040

ABSTRACT A hybrid bilayer membrane (HBM) has been prepared on a glassy carbon electrode (GCE). The HBM consists of an inner layer of n-hexadecylamine (HDA) covalently attached at the GCE and an out-layer of tetra-(N-hexadecylpyridiniurnyl)porphyrin (TC16PyP). The HDA was covalently bounded on the carbon surfaces through its primary amine under cyclic voltammetric potential scans forming a self-assembled monolayer (SAM). The TC16PyP forms a second layer on top of the HDA layer due to hydrophobic interaction. The TC16PyP/HDA/GCE assembly has been utilized to study ion transport through hybrid bilayer membranes. The ion transport through this porphyrin-terminated HBM has been found to strongly dependent on pH. It allows negatively charged redox ions, Fe(CN)63−, to penetrate at pH <6 while repelling positively charged Ru(NH3)63+. However, no faradaic current has been detected at pH >6 with either ions. We believe that electrostatic interaction between the redox ions and the charged membrane is the main reason for this pH dependent ion transport.

  • [Show abstract] [Hide abstract]
    ABSTRACT: L-Asparaginase (l-Asp) is widely used as an effective drug against childhood and adult acute lymphoblastic leukemia (ALL). However, it is immunogenic in humans and may lead to hypersensitivity reactions. The immunological basis of these reactions is not clear. Since the presence of l-Asp specific IgG-antibodies seems to correlate better with clinical reactions than IgE-antibodies and IgG-antibodies are known to be able to fix and activate the complement system, we speculated that the mechanism of anaphylaxis may be complement- rather than IgE-mediated. We analyzed 24 children with ALL (age 2-15 yr) for changes in the complement system during l-Asp infusions. Chemotherapy was administered according to the CoALL 82 protocol which is derived from the CoALL 80 protocol recently published. The formation of specific antibodies of IgM and IgG classes against l-Asp was monitored by a solid phase ELISA. The immunological responsiveness of individual patients varied over a wide range but both types of antibodies were induced. Anaphylactic reactions were observed on eight occasions in eight children. The infusions in the remaining 16 patients were tolerated without clinical reactions. Significant activation of complement was demonstrated in seven of eight reaction occasions and in none of the occasions without reactions. The most important complement activation parameter monitored was the C3 split product C3d measured in EDTA-plasma. We conclude that anaphylaxis to l-Asp in patients with ALL can be explained in most instances on the basis of complement activation induced by the formation of immune complexes of l-Asp and specific antibodies of IgM and IgG classes.
    Pediatric Research 05/1985; 19(4):400-8. · 2.67 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: L-asparaginase, a highly effective anti-leukemic enzyme preparation is now frequently being administered intramuscularly in order to decrease the incidence of severe sensitivity reactions. Although the occurrence of immediate hypersensitivity reactions and anaphylaxis has been diminished through this technique, we report three patients who developed delayed allergic reactions occurring hours after drug administration. This suggests that patients receiving L-asparaginase intramuscularly merit prolonged observation periods beyond the usual one half to one hour.
    Medical and Pediatric Oncology 02/1980; 8(2):123-5.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF), also known as sargramostim, is used to accelerate myeloid recovery following bone marrow transplantation or cytotoxic chemotherapy. "Anaphylactic" reactions to sargramostim have been reported on a limited basis and are poorly characterized. It is the purpose of this report to describe an adverse reaction to sargramostim treatment involving palmar itching, urticaria, angioedema, and throat tightness and to demonstrate the utility of prick skin testing to determine type I sensitization. Prick skin testing with 100 and 250 micrograms/mL sargramostim and 300 micrograms/mL rhu G-CSF (filgrastim) was performed in the patient and four control subjects. The patient experienced an immediate wheal and flare reaction with both concentrations of sargramostim while the control subjects demonstrated no reaction. There was also no reaction with filgrastim (rhu G-CSF) in either group and the patient subsequently tolerated filgrastim therapy. Prick skin testing with rhu GM-CSF and rhu G-CSF may be useful to demonstrate type I sensitization. Additional studies are needed to determine the incidence and prevalence of skin test reactions in larger numbers of patients with cytokine therapy exposure.
    Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology 07/1996; 76(6):531-4. · 3.45 Impact Factor